Clinical Trials Directory

Trials / Completed

CompletedNCT01761643

CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM

CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
398 (actual)
Sponsor
University of California, San Diego · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Accepted

Summary

CCTG 595 is a controlled, open-label, two-arm, randomized (1:1) clinical demonstration project to determine if the use of a text-message based adherence intervention (iTAB) improves retention and adherence to PrEP compared to standard of care (SoC) PrEP delivery.

Detailed description

A total of 400 HIV-uninfected men who have sex with men (MSM)and male to female (M to F) transgender individuals with recent high-risk transmission behavior will be enrolled into the study. Each subject will be followed for up to 48 weeks after enrollment of the last subject. The primary endpoint will be measured at 48 weeks. All subjects will start PrEP with TDF + FTC fixed dose combination given once daily. Subjects will be randomized (1:1) to either the iTAB text messaging adherence reminder intervention with SoC or the SoC alone arm. Subjects placed into the iTAB intervention arm will receive a personalized, automated texting system to maintain adherence and retention. Both groups will receive access to PrEP in accordance with standardized comprehensive methods of prescribing, risk reduction counseling, adherence counseling, and clinical assessments that include safety monitoring, as well as HIV and STD screening. TDF 300 mg + FTC 200 mg fixed dose combination will be given orally once daily starting at the baseline visit (month 0) and continued throughout the study.

Conditions

Interventions

TypeNameDescription
DEVICESoC + iTabText messaging reminders to improve adherence to PrEP

Timeline

Start date
2012-12-19
Primary completion
2018-06-13
Completion
2018-07-11
First posted
2013-01-07
Last updated
2020-06-30
Results posted
2020-06-02

Locations

4 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01761643. Inclusion in this directory is not an endorsement.